emtricitabine + tenofovir disoproxil succinate · Medicine question

Which HIV-1 mutation is a reason to avoid emtricitabine/tenofovir disoproxil in patients previously treated with antiretrovirals?

Name: Which HIV-1 mutation is a reason to avoid emtricitabine/tenofovir disoproxil in patients previously treated with antiretrovirals?
Published: 2026-11-08T01:47:48.603Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Emtricitabine/tenofovir disoproxil should be avoided in patients previously treated with antiretrovirals whose HIV-1 harbours the K65R mutation.

Sources for this answer

Emtricitabine/Tenofovir disoproxil Dr. Reddy's 200 mg/245 mg Film-Coated TabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 11Document updated 26 June 2024

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about emtricitabine + tenofovir disoproxil succinate